Under pressure in diabetes, Novo Nordisk steps up focus on obesity drugs

MÅLØV, Denmark (Reuters) - Danish drugmaker Novo Nordisk is stepping up its efforts to treat obesity, seeking to tap into a potentially huge market as its established diabetes drugs come under price pressure, particularly in the United States.